Actively Recruiting
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Led by Pfizer · Updated on 2026-04-20
162
Participants Needed
32
Research Sites
394 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is being done to learn more about a new medicine called PF-08634404 and how it works when used with other cancer medicines in people who have advanced solid tumors. An advanced solid tumor is a type of cancer that has spread beyond its original location and cannot be removed by surgery or cured with standard treatments. To join in the study, participants must: * Be 18 years or older * Participants with advanced non-small cell lung cancer (NSCLC), a type of lung cancer that has spread The study will look at: * Whether PF-08634404 is safe to use with other cancer medicines. * What side effects may happen. A side effect is anything the medicine does to your body that is not part of treating your disease. * Whether the combination of PF-08634404 and other cancer medicines can help treat solid tumors. The study has different parts, each testing PF-08634404 with a different cancer medicine: * Part A will test PF-08634404 with a medicine called sigvotatug vedotin. * Part B of the study will look at how well the new medicine PF-08634404 works when used together with another medicine. Participants will receive the study medicines through an intravenous (IV) infusion (injected into the vein) at the study clinic. All treatments will take place at clinical trial sites, where trained medical staff will monitor participants during and after each visit.
CONDITIONS
Official Title
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults 18 years or older with pathologically confirmed locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) squamous or non-squamous NSCLC not eligible for complete surgery or curative chemoradiotherapy
- PD-L1 status available
- For Part B only: PD-L1 expression of 1% or higher
- Measurable disease based on RECIST v1.1 criteria
- Eastern Cooperative Oncology Group performance status of 0 or 1
- Adequate organ function as determined by study criteria
You will not qualify if you...
- Known genetic alterations including EGFR, ALK, ROS1, NTRK, BRAF, and MET
- History of another cancer within 3 years before first study treatment or evidence of residual disease from previous cancer
- Active central nervous system lesions such as brainstem, meningeal, or spinal cord metastases or compression
- Leptomeningeal disease
- Active autoimmune diseases requiring systemic treatment within past 2 years
- Previous systemic anti-tumor therapy for locally advanced, unresectable, or metastatic NSCLC
- Previous immunotherapy (except (neo)adjuvant anti-PD-(L)1), antibody-drug conjugates with MMAE payload, systemic anti-angiogenic therapy, or lung radiotherapy within 6 months before first study treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 32 locations
1
Highlands Oncology Group, PA
Fayetteville, Arkansas, United States, 72703
Actively Recruiting
2
Highlands Oncology Group, PA
Rogers, Arkansas, United States, 72758
Actively Recruiting
3
Highlands Oncology Group, PA
Springdale, Arkansas, United States, 72762
Actively Recruiting
4
Providence Medical Foundation
Fullerton, California, United States, 92835
Actively Recruiting
5
Providence St. Jude Medical Center - Virginia K. Crosson Cancer Center and Infusion Center
Fullerton, California, United States, 92835
Actively Recruiting
6
Providence St. Jude Medical Center
Fullerton, California, United States, 92835
Actively Recruiting
7
Rocky Mountain Cancer Centers, LLP
Denver, Colorado, United States, 80218
Actively Recruiting
8
BRCR Medical Center Inc.
Coral Springs, Florida, United States, 33065
Actively Recruiting
9
Mid Florida Hematology and Oncology Center
Orange City, Florida, United States, 32763
Actively Recruiting
10
BRCR Global - Tamarac
Tamarac, Florida, United States, 33321
Actively Recruiting
11
Oncology Associates of Oregon, P.C.
Eugene, Oregon, United States, 97401
Actively Recruiting
12
Dallas Cancer Specialists
Garland, Texas, United States, 75042
Not Yet Recruiting
13
Southwest Oncology Associates
Houston, Texas, United States, 77030
Not Yet Recruiting
14
Lumi Research
Houston, Texas, United States, 77090
Not Yet Recruiting
15
US Oncology Investigational Products Center (IPC)
Irving, Texas, United States, 75063
Actively Recruiting
16
Voyage Clinical
Sugar Land, Texas, United States, 77479
Not Yet Recruiting
17
VCU Medical Center Gateway Building
Richmond, Virginia, United States, 23219
Actively Recruiting
18
Virginia Commonwealth University
Richmond, Virginia, United States, 23219
Actively Recruiting
19
VCU Health Stony Point
Richmond, Virginia, United States, 23235
Actively Recruiting
20
Massey Cancer Center Clinical & Translational Research Lab
Richmond, Virginia, United States, 23298
Actively Recruiting
21
Virginia Commonwealth University
Richmond, Virginia, United States, 23298
Actively Recruiting
22
VCU Health Community Memorial Hospital
South Hill, Virginia, United States, 23970
Actively Recruiting
23
VCU Health Tappahannock Hospital
Tappahannock, Virginia, United States, 22560
Actively Recruiting
24
Kansai Medical University Hospital
Hirakata, Osaka, Japan, 573-1191
Actively Recruiting
25
Shizuoka Cancer Center
Nagaizumi-cho, Shizuoka, Japan, 411-8777
Actively Recruiting
26
Pan American Center for Oncology Trials, LLC
Rio Piedras, Puerto Rico, 00935
Actively Recruiting
27
BRCR Global Puerto Rico - Hato Rey
San Juan, Puerto Rico, 00917
Actively Recruiting
28
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan, 807
Not Yet Recruiting
29
National Cheng Kung University Hospital
Tainan, Taiwan, 704
Not Yet Recruiting
30
National Taiwan University Hospital
Taipei, Taiwan, 100
Not Yet Recruiting
31
Mackay Memorial Hospital
Taipei, Taiwan, 10449
Not Yet Recruiting
32
Taipei Veterans General Hospital
Taipei, Taiwan, 11217
Not Yet Recruiting
Research Team
P
Pfizer CT.gov Call Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here